Pfizer Receives EU Approval for Xeljanz (tofacitinib citrate, JAK3i) for Moderate to Severe UC Patients
Pfizer Receives EU Approval for Xeljanz (tofacitinib citrate, JAK3i) for Moderate to Severe UC Patients
Shots:
- EU has approved intake of Xeljanz 10mg BID for 8 weeks followed by 5mg or 10mg for moderate to active UC in adults
- Xeljanz is now approved in three indication including UC, since 2017, in combination with MTX for RA and for active PsA, approved by EU
- This approval is based on the data from three pivotal Ph 3 study from OCTAVE (Induction 1 & 2 and Sustain)
Click here to read full press release/ article | Ref: Pfizer | Image: Fortune